Geode Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-624,146
Closed -$3.22M 4301
2019
Q2
$3.22M Buy
624,146
+52,062
+9% +$234K ﹤0.01% 2648
2019
Q1
$2.06M Buy
572,084
+45,755
+9% +$198K ﹤0.01% 2828
2018
Q4
$3.23M Buy
526,329
+91,968
+21% +$561K ﹤0.01% 2492
2018
Q3
$2.54M Buy
434,361
+31,312
+8% +$156K ﹤0.01% 2758
2018
Q2
$1.71M Buy
403,049
+86,114
+27% +$434K ﹤0.01% 2942
2018
Q1
$1.4M Buy
316,935
+3,309
+1% +$14.8K ﹤0.01% 2960
2017
Q4
$1.65M Buy
313,626
+21,654
+7% +$132K ﹤0.01% 2862
2017
Q3
$1.79M Buy
291,972
+5,373
+2% +$34K ﹤0.01% 2818
2017
Q2
$2.07M Buy
286,599
+43,247
+18% +$266K ﹤0.01% 2712
2017
Q1
$1.29M Buy
243,352
+10,465
+4% +$70.7K ﹤0.01% 2894
2016
Q4
$1.67M Buy
232,887
+26,332
+13% +$213K ﹤0.01% 2726
2016
Q3
$1.93M Buy
206,555
+17,370
+9% +$144K ﹤0.01% 2579
2016
Q2
$1.2M Buy
189,185
+5,304
+3% +$34.1K ﹤0.01% 2804
2016
Q1
$1.01K Buy
183,881
+2,550
+1% +$9.59K ﹤0.01% 2872
2015
Q4
$1.01M Buy
181,331
+1,551
+0.9% +$10.3K ﹤0.01% 2909
2015
Q3
$1.52M Buy
179,780
+4,063
+2% +$68.8K ﹤0.01% 2617
2015
Q2
$2.66M Buy
175,717
+997
+0.6% +$14.4K ﹤0.01% 2317
2015
Q1
$2.8M Buy
174,720
+2,697
+2% +$48K ﹤0.01% 2225
2014
Q4
$3.06M Buy
172,023
+49,210
+40% +$613K ﹤0.01% 2132
2014
Q3
$1.23M Buy
122,813
+15,961
+15% +$194K ﹤0.01% 2662
2014
Q2
$1.67M Buy
106,852
+12,436
+13% +$176K ﹤0.01% 2490
2014
Q1
$1.75M Buy
94,416
+60,226
+176% +$1.21M ﹤0.01% 2415
2013
Q4
$653K Buy
34,190
+732
+2% +$14.9K ﹤0.01% 2950
2013
Q3
$547K Buy
+33,458
New +$352K ﹤0.01% 2903

Other funds holding PETX

Geode Capital Management's PETX Position: Q3 2019 in Review

Geode Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 624,146 shares — an estimated $3.22M sold.

Geode Capital Management first reported a position in PETX in Q3 2013 and held it in 24 quarters. The position peaked at $3.23M in Q4 2018. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

  • Geode Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Geode Capital Management sold 624,146 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $3.22M.
  • Geode Capital Management first reported a position in Aratana Therapeutics, Inc. in Q3 2013 and held it in 24 quarters.
  • Geode Capital Management's Aratana Therapeutics, Inc. position peaked at $3.23M in Q4 2018.
  • 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on Geode Capital Management's 13F filing for Q3 2019, filed 12 Nov 2019.